2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1282

Effect of RC-3095, An Antagonist of Gastrin-Releasin Peptide Receptor, Regulating Synovial Fibroblasts in Experimental Arthritis
Abstract Number: 608

Effect Of Renal Damage On Extra-Renal Organ Damage and Mortality In Patients With Systemic Lupus Erythematosus (SLE): A Longitudinal Cohort Study Of 756 Patients
Abstract Number: 1548

Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Abstract Number: 2344

Effect Of Tocilizumab On Treatment Patterns, Effectiveness and Safety With Laboratory Values For Patients With Rheumatoid Arthritis: Analyses From The Corrona-Certain Study
Abstract Number: 1552

Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial
Abstract Number: 1205

Effectiveness Of Canakinumab In a Cryopyrin-Associated Periodic Syndrome Cohort.A Single Center Experience
Abstract Number: 1476

Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Abstract Number: 2438

Effectiveness Of Exercise Program in Ankylosing Spondylitis: Meta-Analysis Of Randomized Controlled Trials
Abstract Number: 1784

Effectiveness Of First Line Use Of Recombinant IL-1RA Treatment In Steroid naïve Systemic Juvenile Idiopathic Arthritis: Results Of a Prospective Cohort Study
Abstract Number: 1106

Effectiveness Of Interdisciplinary Program For Fibromyalgia
Abstract Number: 1819

Effectiveness Of Pilates Method For The Treatment Of Chronic Mechanical Neck PAIN
Abstract Number: 496

Effectiveness Of Repeated Courses Of Rituximab In RA – Results From The Cererra Collaboration
Abstract Number: 1435

Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry
Abstract Number: 448

Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study
Abstract Number: 2796

Effects Of BAFF Inhibition On B Cell Selection In Murine SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].